AstraZeneca Asthma Candidate Tralokinumab Fails Two Phase III Trials

AstraZeneca acknowledged today that its anti-interleukin-13 (anti-IL-13) human monoclonal antibody (mAb) tralokinumab has failed its second and third Phase III trials in severe, uncontrolled asthma.The pharma giant announced topline results from the two trials, STRATOS 2 ( NCT02194699 ) and TROPOS ( NCT02281357 ). In the 858-patient STRATOS 2, tralokinumab did not achieve a statistically-significant reduction in the study’s primary endpoint of annual asthma exacerbation rate (AAER) in pati